What the FDA labels say about taking them together
Cobicistat and oxcarbazepine
Cobicistat's FDA label of February 10, 2026 names oxcarbazepine in its drug interactions section; the oxcarbazepine labels PlainMeds reads (2) do not name cobicistat. The cobicistat label: “Consider alternative anticonvulsant or antiretroviral therapy to avoid potential changes in exposures. If coadministration is necessary, monitor for lack or loss of virologic response.”
Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the oxcarbazepine FDA label on DailyMed (effective December 16, 2025, Novartis Pharmaceuticals Corporation).
What does the cobicistat label say about oxcarbazepine?
Cobicistat label, drug interactionsConcomitant Drug Class/Drug Name: Anticonvulsants with CYP3A induction effects that are NOT contraindicated e.g., eslicarbazepine, oxcarbazepine; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↓ cobicistat ↓ atazanavir darunavir: effect unknown; Clinical Comment: Consider alternative anticonvulsant or antiretroviral therapy to avoid potential changes in exposures. If coadministration is necessary, monitor for lack or loss of virologic response.
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
What does the oxcarbazepine label say about cobicistat?
Oxcarbazepine's label (effective December 16, 2025) and its 1 other brand-application label do not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Trileptal), Novartis Pharmaceuticals Corporation, effective December 16, 2025 (SPL set 4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat | Oxcarbazepine | |
|---|---|---|
| Labeled for | HIV | Seizures and epilepsy |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.167 per tablet 300 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once